Key result
Intravenous infusion of U.K. 14275 enhanced the contractile state of the left ventricle without altering the heart rate in patients with coronary heart disease.
Why the study?
Does intravenous U.K. 14275 improve left ventricular function in patients with coronary heart disease?
Does intravenous U.K. 14275 improve left ventricular function in patients with coronary heart disease?
Intravenous infusion of the phosphodiesterase inhibitor U.K. 14275 enhances left ventricular contractility without affecting heart rate in patients with coronary heart disease.
Should not yet change practice in coronary disease; hypothesis-generating for heart rate-independent inotropy.
1 The chronotropic and inotropic properties of U.K. 14275, a phosphodiesterase inhibitor were assessed in patients with coronary heart disease. 2 Left ventricular function was assessed in eight patients with acute myocardial infarction using the non-invasive measurement of systolic time intervals. 3 Twelve patients with angina pectoris were studied during diagnostic coronary arteriography. Left ventricular function was assessed using a high fidelity catheter tipped transducer in the left ventricle. 4 In both groups of patients U.K. 14275 infused intravenously in doses of 32, 64, 128 and 256 microgram kg-1 bodyweight min-1 enhanced the contractile state of the left ventricle without altering the heart rate.
No takes yet. Share an insight, caveat, or question.
Hutton et al. (1977) studied Coronary heart disease (n=20). U.K. 14275 was evaluated on Left ventricular function (contractile state and heart rate). Intravenous infusion of U.K. 14275 enhanced the contractile state of the left ventricle without altering the heart rate in patients with coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: